3 Biotechs That Have Doubled Investors' Money in Less Than a Year
Having a stock double in value is a good thing. Source: BioSpace
Having a stock double in value is a good thing. Source: BioSpace
The latest acquisition makes it the highest amount paid for a flex R&D building in Los Angeles County. Source: BioSpace
Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage studies. Source: BioSpace
The company expects the new facility will include commercial manufacturing capabilities in 18 to 24 months. Source: BioSpace
The companies will collaborate on research to study a previously unrecognized role for peripheral immune cells in the pathology of central nervous system disorders. Source: BioSpace
The announcement sent shares of Juno soaring more than 27 percent in pre-market trading to $86.26. Source: BioSpace
Marshall co-founded more than a decade ago, and which was acquired by Sosei in 2015. Source: BioSpace
The deal has Sanofi paying $105 per share in cash. Source: BioSpace
Acorn Pacific Ventures led the round, with participation from GP Capital and all existing major investors. Source: BioSpace
Indalo Therapeutics is based in St. Louis and was formed in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics. Source: BioSpace